Xbrane Biopharma: Ximluci Approved in the UK - Redeye

Redeye endorses that the MHRA has granted marketing authorization for Ximluci® in the UK. Today’s news is very positive as the UK is a large market, but it was also expected, considering Ximluci®already being approved in the EU. We reiterate our SEK180 base case and continue to see a pivotal year ahead of Xbrane. The EU launch of Ximluci® is imminent, and 2023 should contain several high-impact catalysts to support the share price trajectory.

Länk till analysen i sin helhet: https://www.redeye.se/research/871230/xbrane-biopharma-ximluci-approved-in-the-uk?utm_source=finwire&utm_medium=RSS